Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Aravax Pty Ltd. is active in the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action. This action is assigned to 1 distinct art unit. NORA MAUREEN ROONEY is the busiest examiner, overseeing the 1 pending action. There is only 1 distinct examiner involved in the company's current prosecution.
This indicates that the company's pending activity is entirely concentrated within one art unit and under one examiner. For a Biotechnology & Pharmaceuticals portfolio, the pending action and the distinct examiner represent a very focused point of interaction with the patent office.
The alignment of the action with the examiner and art unit means that the company's current success in the Biotechnology & Pharmaceuticals field is tied to a single review process. Practitioners should focus their efforts on the specific requirements of NORA MAUREEN ROONEY within the art unit. This concentration simplifies the management of the company's current pending portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROONEY, NORA MAUREEN | 1 | 60.5% | +23.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18754670 | NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF | ROONEY, NORA MAUREEN | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18754670 | NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF | ROONEY, NORA MAUREEN | 14d |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18754670 | NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF | ROONEY, NORA MAUREEN | 1641 | §102§103 | Non-Final OA | 14d | Pending | Jun 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAravax Pty Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nora Maureen Rooney has the most, with 1 of Aravax Pty Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
